Search

Your search keyword '"Scimè, Rosanna"' showing total 27 results
Start Over Author "Scimè, Rosanna" Search Limiters Full Text
27 results on '"Scimè, Rosanna"'

1. Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation

Author

Ruggeri, Annalisa, de Wreede, Liesbeth C., Müller, Carlheinz R., Crivello, Pietro, Bonneville, Edouard F., Petersdorf, Effie W., Socié, Gerard, Dubois, Valérie, Niittyvuopio, Riitta, Peräsaari, Juha, Yakoub-Agha, Ibrahim, Cornelissen, Jan J., Wieten, Lotte, Gedde-Dahl, Tobias, Forcade, Edouard, Crawley, Charles R., Marsh, Steven G.E., Gandemer, Virginie, Tholouli, Eleni, Bulabois, Claude-Eric, Huynh, Anne, Choi, Goda, Deconinck, Eric, Itäla-Remes, Maija, Lenhoff, Stig, Bengtsson, Mats, Johansson, Jan-Erik, van Gorkom, Gwendolyn, Hoogenboom, Jorinde D., Vago, Luca, Rocha, Vanderson, Bonini, Chiara, Chabannon, Christian, Fleischhauer, Katharina, Clausen, Johannes, Holter, Wolfgang, Kalhs, Peter, Beguin, Yves, Bron, Dominique, Deeren, Dries, Lung, Wu Ka, Kerre, Tessa, Poiré, Xavier, Selleslag, Dominik, Schroyens, Wilfried, Jindra, Pavel, Mayer, Jiri, Vydra, Jan, Zák, Pavel, Nielsen, Bendt, Sengeloev, Henrik, Kaare, Ain, Partanen, Anu, Bay, Jacques-Olivier, Bertrand, Yves, Blaise, Didier, Bourhis, Jean Henri, Chevallier, Patrice, Cluzeau, Thomas, Damaj, Gandhi, Fegueux, Nathalie, Guyotat, Denis, Hunault-Berger, Mathilde, Labussière-Wallet, Hélène, Leleu, Xavier, Lioure, Bruno, Maury, Sebastien, Michel, Gérard, Mohty, Mohamad, Rubio, Marie Thérèse, Tilly, Herve, Turlure, Pascal, Bethge, Wolfgang, Casper, Jochen, Einsele, Hermann, Ganser, Arnold, Kröger, Nicolaus, Martin, Sonja, Platzbecker, Uwe, Reinhardt, Christian, Schäfer-Eckart, Kerstin, Thurner, Lorenz, Valerius, Thomas, Wulf, Gerald G., Karakasis, Dimitrios, Spyridonidis, Alexandros, Hauser, Peter, Reményi, Péter, Reykdal, Sigrun, Mousavi, Ashrafsadat, Angelucci, Emanuele, Arcese, William, Benedetti, Fabio, Bernasconi, Paolo, Biondi, Andrea, Bonifazi, Francesca, Carella, Angelo Michele, Carluccio, Paola, Casini, Marco, Cavanna, Luigi, Ciceri, Fabio, Cimino, Giuseppe, Corradini, Paolo, Fanin, Renato, Galieni, Piero, Grillo, Giovanni, Iori, Anna Paola, La Nasa, Giorgio, Locatelli, Franco, Marotta, Giuseppe, Martino, Massimo, Mazza, Patrizio, Mordini, Nicola, Musso, Maurizio, Olivieri, Attilio, Pavone, Vincenzo, Pane, Fabrizio, Petrini, Mario, Pioltelli, Pietro, Rambaldi, Alessandro, Ruggeri, Marco, Saccardi, Riccardo, Santarone, Stella, Scimè, Rosanna, Sica, Simona, Tarella, Corrado, Velardi, Andrea, Visani, Giuseppe, Zecca, Marco, Tanase, Alina, Kulagin, Aleksandr, Savchenko, Valery, López, Carmen Albo, Amor, Adrián Alegre, López, Jose Luis Bello, Caballero, Dolores, Duarte, Rafael, Cascon, Maria Jesús Pascual, Porras, Rocio Parody, Pérez-Simón, Jose Antonio, Rovira, Montserrat, Sanz, Jaime, Carrete, Juan Pio Torres, Cammenga, Jörg, Isaksson, Cecilia, Mielke, Stephan, Chalandon, Yves, Passweg, Jakob, Schanz, Urs, Meijer, Ellen, Kuball, Jürgen, Veelken, Joan Hendrik, Apperley, Jane, Bloor, Adrian, Byrne, Jenny, Carpenter, Ben, Clark, Andrew, Collin, Matthew, Craddock, Charles, Gibson, Brenda E., Khan, Anjum, Martin, Murray, Medd, Patrick, Nicholson, Emma, Orchard, Kim, Patel, Amit, Peniket, Andy, Potter, Victoria, Snowden, John, Wilson, Keith M.O., RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Transplant. Immunology/Tissue Typing lab, Interne Geneeskunde, MUMC+: MA Hematologie (9), Hematology, IRCCS San Raffaele Scientific Institute [Milan, Italie], EFS, CHU Lille, Erasmus University Medical Center [Rotterdam] (Erasmus MC), Maastricht University Medical Centre (MUMC), Maastricht University [Maastricht], Oslo University Hospital [Oslo], CHU Bordeaux [Bordeaux], CHU Pontchaillou [Rennes], Institut de Génétique et Développement de Rennes (IGDR), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), University of Groningen [Groningen], Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), and Essen University Hospital

Subjects
Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA, [SDV]Life Sciences [q-bio], HSCT, Medizin, Hematology, Hematologi
Abstract

International audience; Not available.

Published
2023
Full Text
View/download PDF

2. Allogeneic Hematopoietic Cell Transplantation from Unrelated Donors in Multiple Myeloma: Study from the Italian Bone Marrow Donor Registry

Author

Passera, Roberto, Pollichieni, Simona, Brunello, Lucia, Patriarca, Francesca, Bonifazi, Francesca, Montefusco, Vittorio, Falda, Michele, Montanari, Mauro, Guidi, Stefano, Giaccone, Luisa, Mordini, Nicola, Carella, Angelo Michele, Bavaro, Pasqua, Milone, Giuseppe, Benedetti, Fabio, Ciceri, Fabio, Scimè, Rosanna, Benedetti, Edoardo, Castagna, Luca, Festuccia, Moreno, Rambaldi, Alessandro, Bacigalupo, Andrea, Corradini, Paolo, Bosi, Alberto, Boccadoro, Mario, Bandini, Giuseppe, Fanin, Renato, and Bruno, Benedetto

Published
2013
Full Text
View/download PDF

3. Consistent bone marrow-derived cell mobilization following repeated short courses of granulocyte–colony-stimulating factor in patients with amyotrophic lateral sclerosis: results from a multicenter prospective trial

Author

Tarella, Corrado, Rutella, Sergio, Gualandi, Francesca, Melazzini, Mario, Scimè, Rosanna, Petrini, Mario, Moglia, Cristina, Ulla, Marco, Omedé, Paola, Bella, Vincenzo La, Corbo, Massimo, Silani, Vincenzo, Siciliano, Gabriele, Mora, Gabriele, Caponnetto, Claudia, Sabatelli, Mario, and Chiò, Adriano

Published
2010
Full Text
View/download PDF

4. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti–thymocyte globulin

Author

Van Lint, Maria Teresa, Milone, Giuseppe, Leotta, Salvatore, Uderzo, Cornelio, Scimè, Rosanna, Dallorso, Sandro, Locasciulli, Anna, Guidi, Stefano, Mordini, Nicola, Sica, Simona, Cudillo, Laura, Fagioli, Franca, Selleri, Carmine, Bruno, Barbara, Arcese, William, and Bacigalupo, Andrea

Published
2006
Full Text
View/download PDF

5. Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey

Author

Girmenia, Corrado, Bertaina, Alice, Piciocchi, Alfonso, Perruccio, Katia, Algarotti, Alessandra, Busca, Alessandro, Cattaneo, Chiara, Raiola, Anna Maria, Guidi, Stefano, Iori, Anna Paola, Candoni, Anna, Irrera, Giuseppe, Milone, Giuseppe, Marcacci, Giampaolo, Scimè, Rosanna, Musso, Maurizio, Cudillo, Laura, Sica, Simona, Castagna, Luca, Corradini, Paolo, Marchesi, Francesco, Pastore, Domenico, Alessandrino, Emilio Paolo, Annaloro, Claudio, Ciceri, Fabio, Santarone, Stella, Nassi, Luca, Farina, Claudio, Viscoli, Claudio, Rossolini, Gian Maria, Bonifazi, Francesca, Rambaldi, Alessandro, Capria, Saveria, Bertaina, A., Mastronuzzi, Angela, Pagliara, Daria, Bernaschi, Paola, Amico, Lucia, Carotti, Alessandra, Mencacci, Antonella, Busca, A., Bruno, Benedetto, Costa, Cristina, Passi, Angela, Ravizzola, Giuseppe, Angelucci, Emanuele, Marchese, Anna, Pecile, Patrizia, Candoni, A., Ventura, Giovanna, Fanin, Renato, Scarparo, Claudio, Barbaro, Angelo, Milone, G., Leotta, Salvatore, Marchese, Anna Elisa, Marcacci, G., Becchimanzi, Cristina, Donnarumma, Daniela, Tringali, Stefania, Baldi, Maria Teresa, Scalone, Renato, Cudillo, L., Picardi, Alessandra, Arcese, William, Fontana, Carla, Sica, S., Giammarco, Sabrina, Spanu, Teresa, Castagna, L., Crocchiolo, Roberto, Casari, Erminia, Mussetti, Alberto, Conte, Eutilia, Ensoli, Fabrizio, Miragliotta, Giuseppe, Marone, Piero, Arghittu, Milena, Greco, Raffaella, Forcina, Alessandra, Chichero, Paola, Santarone, S., Di Bartolomeo, Paolo, Fazii, Paolo, Kroumova, Vesselina, Decembrino, Nunzia, Zecca, Marco, Pisapia, Giovanni, Palazzo, Giulia, Lanino, Edoardo, Faraci, Maura, Castagnola, Elio, Bandettini, Roberto, Pastano, Rocco, Sammassimo, Simona, Passerini, Rita, Stefani, Piero Maria, Gherlinzoni, Filippo, Rigoli, Roberto, Prezioso, Lucia, Cambò, Benedetta, Calderaro, Adriana, Carella, Angelo Michele, Cascavilla, Nicola, Labonia, Maria Teresa, Celeghini, Ivana, Mordini, Nicola, Piana, Federica, Vacca, Adriana, Sanna, Marco, Podda, Giovanni, Corsetti, Maria Teresa, Rocchetti, Andrea, Cilloni, Daniela, De Gobbi, Marco, Bianco, Ornella, Fagioli, Franca, Carraro, Francesca, De Intinis, Gianfranco, Severino, Alessandro, Proia, Anna, Parisi, Gabriella, Vallisa, Daniele, Confalonieri, Massimo, Russo, Domenico, Malagola, Michele, Galieni, Piero, Falcioni, Sadia, Travaglini, Valeria, Raimondi, Roberto, Borghero, Carlo, Pavan, Giacomina, Prete, Arcangelo, Belotti, Tamara, Ambretti, Simone, Imola, Manuela, Mianulli, Anna Maria, Pedna, Maria Federica, Cesaro, Simone, Lo Cascio, Giuliana, Ferrari, Antonella, Piedimonte, Monica, Santino, Iolanda, Calandrelli, Monica, Olivieri, Attilio, Orecchioni, Francesca, Mirabile, Milena, Centurioni, Riccardo, Gironacci, Luciana, Caravelli, Daniela, Gallo, Susanna, De Filippi, Marco, Cupelli, Luca, Dentamaro, Teresa, Falco, Silvana, Eugenio, Ospedale S, Marotta, Serena, Risitano, Antonio, Lula, Dora, Musto, Pellegrino, Pietrantuono, Giuseppe, Traficante, Antonio, Cerchiara, Elisabetta, Tirindelli, Maria Cristina, Dicuonzo, Giordano, Chierichini, Anna, Anaclerico, Barbara, Placanica, Paola, Girmenia, C, Bertaina, A, Piciocchi, A, Perruccio, K, Algarotti, A, Busca, A, Cattaneo, C, Raiola, Am, Guidi, S, Iori, Ap, Candoni, A, Irrera, G, Milone, G, Marcacci, G, Scimè, R, Musso, M, Cudillo, L, Sica, S, Castagna, L, Corradini, P, Marchesi, F, Pastore, D, Alessandrino, Ep, Annaloro, C, Ciceri, F, Santarone, S, Nassi, L, Farina, C, Viscoli, C, Rossolini, Gm, Bonifazi, F, Rambaldi, A, for the Gruppo Italiano Trapianto di Midollo Osseo, (GITMO), Associazione Microbiologi Clinici Italiani, (AMCLI), Girmenia, Corrado, Bertaina, Alice, Piciocchi, Alfonso, Perruccio, Katia, Algarotti, Alessandra, Busca, Alessandro, Cattaneo, Chiara, Raiola, Anna Maria, Guidi, Stefano, Iori, Anna Paola, Candoni, Anna, Irrera, Giuseppe, Milone, G., Marcacci, Giampaolo, Scimè, Rosanna, Musso, Maurizio, Cudillo, Laura, Sica, Simona, Castagna, Luca, Corradini, Paolo, Marchesi, Francesco, Pastore, Domenico, Alessandrino, Emilio Paolo, Annaloro, Claudio, Ciceri, Fabio, Santarone, Stella, Nassi, Luca, Farina, Claudio, Viscoli, Claudio, Rossolini, Gian Maria, Bonifazi, Francesca, Rambaldi, Alessandro, Capria, Saveria, Bertaina, A., Mastronuzzi, Angela, Pagliara, Daria, Bernaschi, Paola, Amico, Lucia, Carotti, Alessandra, Mencacci, Antonella, Busca, A., Bruno, Benedetto, Costa, Cristina, Passi, Angela, Ravizzola, Giuseppe, Angelucci, Emanuele, Marchese, Anna, Pecile, Patrizia, Candoni, A., Ventura, Giovanna, Fanin, Renato, Scarparo, Claudio, Barbaro, Angelo, Leotta, Salvatore, Marchese, Anna Elisa, Marcacci, G., Becchimanzi, Cristina, Donnarumma, Daniela, Tringali, Stefania, Baldi, Maria Teresa, Scalone, Renato, Cudillo, L., Picardi, Alessandra, Arcese, William, Fontana, Carla, Sica, S., Giammarco, Sabrina, Spanu, Teresa, Castagna, L., Crocchiolo, Roberto, Casari, Erminia, Mussetti, Alberto, Conte, Eutilia, Ensoli, Fabrizio, Miragliotta, Giuseppe, Marone, Piero, Arghittu, Milena, Greco, Raffaella, Forcina, Alessandra, Chichero, Paola, Santarone, S., Di Bartolomeo, Paolo, Fazii, Paolo, Kroumova, Vesselina, Decembrino, Nunzia, Zecca, Marco, Pisapia, Giovanni, Palazzo, Giulia, Lanino, Edoardo, Faraci, Maura, Castagnola, Elio, Bandettini, Roberto, Pastano, Rocco, Sammassimo, Simona, Passerini, Rita, Stefani, Piero Maria, Gherlinzoni, Filippo, Rigoli, Roberto, Prezioso, Lucia, Cambò, Benedetta, Calderaro, Adriana, Carella, Angelo Michele, Cascavilla, Nicola, Labonia, Maria Teresa, Celeghini, Ivana, Mordini, Nicola, Piana, Federica, Vacca, Adriana, Sanna, Marco, Podda, Giovanni, Corsetti, Maria Teresa, Rocchetti, Andrea, Cilloni, Daniela, De Gobbi, Marco, Bianco, Ornella, Fagioli, Franca, Carraro, Francesca, De Intinis, Gianfranco, Severino, Alessandro, Proia, Anna, Parisi, Gabriella, Vallisa, Daniele, Confalonieri, Massimo, Russo, Domenico, Malagola, Michele, Galieni, Piero, Falcioni, Sadia, Travaglini, Valeria, Raimondi, Roberto, Borghero, Carlo, Pavan, Giacomina, Prete, Arcangelo, Belotti, Tamara, Ambretti, Simone, Imola, Manuela, Mianulli, Anna Maria, Pedna, Maria Federica, Cesaro, Simone, Lo Cascio, Giuliana, Ferrari, Antonella, Piedimonte, Monica, Santino, Iolanda, Calandrelli, Monica, Olivieri, Attilio, Orecchioni, Francesca, Mirabile, Milena, Centurioni, Riccardo, Gironacci, Luciana, Caravelli, Daniela, Gallo, Susanna, De Filippi, Marco, Cupelli, Luca, Dentamaro, Teresa, Falco, Silvana, Eugenio, Ospedale S, Marotta, Serena, Risitano, Antonio, Lula, Dora, Musto, Pellegrino, Pietrantuono, Giuseppe, Traficante, Antonio, Cerchiara, Elisabetta, Tirindelli, Maria Cristina, Dicuonzo, Giordano, Chierichini, Anna, Anaclerico, Barbara, and Placanica, Paola

Subjects
0301 basic medicine, Male, Transplantation Conditioning, Drug Resistance, Bacteremia, 0302 clinical medicine, epidemiology, Gram negative bacteremia, multidrug resistance, stem cell transplant, survival, Risk Factors, Drug Resistance, Multiple, Bacterial, Epidemiology, Medicine, Age Factor, Prospective Studies, Prospective cohort study, Child, Transplantation, Homologou, education.field_of_study, Incidence (epidemiology), Incidence, Bacterial, Age Factors, Hematopoietic Stem Cell Transplantation, Middle Aged, Transplantation, Autologou, surgical procedures, operative, Infectious Diseases, Italy, Child, Preschool, Female, medicine.symptom, Multiple, Autologous, Human, Homologous, Microbiology (medical), Adult, medicine.medical_specialty, Adolescent, 030106 microbiology, Population, Transplantation, Autologous, 03 medical and health sciences, Young Adult, Internal medicine, Gram-Negative Bacteria, Gram-Negative Bacterial Infection, Escherichia coli, Humans, Transplantation, Homologous, Preschool, education, Aged, Gram-Negative Bacterial Infections, Infant, Transplantation, business.industry, Risk Factor, medicine.disease, Prospective Studie, Carriage, Otitis, business, Settore MED/15 - Malattie del Sangue, 030215 immunology
Abstract

Background Gram-negative bacteremia (GNB) is a major cause of illness and death after hematopoietic stem cell transplantation (HSCT), and updated epidemiological investigation is advisable. Methods We prospectively evaluated the epidemiology of pre-engraftment GNB in 1118 allogeneic HSCTs (allo-HSCTs) and 1625 autologous HSCTs (auto-HSCTs) among 54 transplant centers during 2014 (SIGNB-GITMO-AMCLI study). Using logistic regression methods. we identified risk factors for GNB and evaluated the impact of GNB on the 4-month overall-survival after transplant. Results The cumulative incidence of pre-engraftment GNB was 17.3% in allo-HSCT and 9% in auto-HSCT. Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa were the most common isolates. By multivariate analysis, variables associated with GNB were a diagnosis of acute leukemia, a transplant from a HLA-mismatched donor and from cord blood, older age, and duration of severe neutropenia in allo-HSCT, and a diagnosis of lymphoma, older age, and no antibacterial prophylaxis in auto-HSCT. A pretransplant infection by a resistant pathogen was significantly associated with an increased risk of posttransplant infection by the same microorganism in allo-HSCT. Colonization by resistant gram-negative bacteria was significantly associated with an increased rate of infection by the same pathogen in both transplant procedures. GNB was independently associated with increased mortality at 4 months both in allo-HSCT (hazard ratio, 2.13; 95% confidence interval, 1.45–3.13; P Conclusions Pre-engraftment GNB is an independent factor associated with increased mortality rate at 4 months after auto-HSCT and allo-HSCT. Previous infectious history and colonization monitoring represent major indicators of GNB. Clinical Trials registration NCT02088840.

Published
2017

7. Phase II Multicenter, Not Comparative, Study of Multiple Doses of NEPA (netupitant + palonosetron) in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in Non-Hodgkin Lymphoma Patients Eligible for Autologous Hematopoietic Stem Cell Transplantation Receiving Multiple Days / High Dose Chemotherapy Regimens

Author

Di Renzo, Nicola, primary, Musso, Maurizio, additional, Scimè, Rosanna, additional, Milone, Giuseppe, additional, Perrone, Tommasina, additional, De Risi, Clara, additional, Pastore, Domenico, additional, Guarini, Attilio, additional, Mengarelli, Andrea, additional, Benedetti, Fabio, additional, Mazza, Patrizio, additional, Capria, Vera, additional, Chiusolo, Patrizia, additional, Cupelli, Luca, additional, Federico, Vincenzo, additional, Bozzoli, Valentina, additional, Messa, Anna Rita, additional, and Specchia, Giorgina, additional

Published
2019
Full Text
View/download PDF

8. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: An open-label, multicentre, randomised, phase 3 trial

Author

Rambaldi, Alessandro, Grassi, Anna, Masciulli, Arianna, Boschini, Cristina, Micò, Maria Caterina, Busca, Alessandro, Di Benedetto, Bruno, Cavattoni, Irene, Santarone, Stella, Raimondi, Roberto, Montanari, Mauro, Milone, Giuseppe, Chiusolo, Patrizia, Pastore, Domenico, Guidi, Stefano, Patriarca, Francesca, Risitano, Antonio M., Saporiti, Giorgia, Pini, Massimo, Terruzzi, Elisabetta, Arcese, William, Marotta, Giuseppe, Carella, Angelo Michele, Nagler, Arnon, Russo, Domenico, Corradini, Paolo, Alessandrino, Emilio Paolo, Torelli, Giovanni Fernando, Scimè, Rosanna, Mordini, Nicola, Oldani, Elena, Marfisi, Rosa Maria, Bacigalupo, Andrea, Bosi, Alberto, Chiusolo, Patrizia (ORCID:0000-0002-1355-1587), Bacigalupo, Andrea (ORCID:0000-0002-9119-567X), Rambaldi, Alessandro, Grassi, Anna, Masciulli, Arianna, Boschini, Cristina, Micò, Maria Caterina, Busca, Alessandro, Di Benedetto, Bruno, Cavattoni, Irene, Santarone, Stella, Raimondi, Roberto, Montanari, Mauro, Milone, Giuseppe, Chiusolo, Patrizia, Pastore, Domenico, Guidi, Stefano, Patriarca, Francesca, Risitano, Antonio M., Saporiti, Giorgia, Pini, Massimo, Terruzzi, Elisabetta, Arcese, William, Marotta, Giuseppe, Carella, Angelo Michele, Nagler, Arnon, Russo, Domenico, Corradini, Paolo, Alessandrino, Emilio Paolo, Torelli, Giovanni Fernando, Scimè, Rosanna, Mordini, Nicola, Oldani, Elena, Marfisi, Rosa Maria, Bacigalupo, Andrea, Bosi, Alberto, Chiusolo, Patrizia (ORCID:0000-0002-1355-1587), and Bacigalupo, Andrea (ORCID:0000-0002-9119-567X)

Abstract

Background: The standard busulfan-cyclophosphamide myeloablative conditioning regimen is associated with substantial non-relapse mortality in patients older than 40 years with acute myeloid leukaemia who are undergoing allogeneic stem-cell transplantation. Because the combination of busulfan plus fludarabine has been proposed to reduce non-relapse mortality, we aimed to compare this treatment with busulfan plus cyclophosphamide as a preparative regimen in these patients. Methods: We did an open-label, multicentre, randomised, phase 3 trial for patients with acute myeloid leukaemia at 25 hospital transplant centres in Italy and one in Israel. Eligible patients were aged 40-65 years, had an Eastern Cooperative Oncology Group performance status less than 3, and were in complete remission. Patients were randomly assigned 1:1 to receive intravenous busulfan plus cyclophosphamide or busulfan plus fludarabine. Treatment allocations were not masked to investigators or patients. Randomisation was done centrally via a dedicated web-based system using remote data entry, with patients stratified by donor type and complete remission status. Patients allocated to busulfan plus cyclophosphamide received intravenous busulfan 0·8 mg/kg four times per day during 2 h infusions for four consecutive days (16 doses from days -9 through -6; total dose 12·8 mg/kg) and cyclophosphamide at 60 mg/kg per day for two consecutive days (on days -4 and -3; total dose 120 mg/kg). Patients allocated to busulfan plus fludarabine received the same dose of intravenous busulfan (from days -6 through -3) and fludarabine at 40 mg/m2per day for four consecutive days (from days -6 through -3; total dose 160 mg/m2). The primary endpoint was 1-year non-relapse mortality, which was assessed on an intention-to-treat basis; safety outcomes were assessed in the per-protocol population. This trial has been completed and is registered with ClinicalTrials.gov, number NCT01191957. Findings: Between Jan 3, 2008, and D

Published
2015

10. Randomized Trial of Busulfan with Cyclophosphamide Versus Busulfan with Fludarabine As Preparative Regimen to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia: A Study from the Gruppo Italiano Trapianto Midollo Osseo (GITMO)

Author

Rambaldi, Alessandro, primary, Grassi, Anna, additional, Micò, Maria Caterina, additional, Busca, Alessandro, additional, Bruno, Benedetto, additional, Cavattoni, Irene, additional, Santarone, Stella, additional, Raimondi, Roberto, additional, Montanari, Mauro, additional, Milone, Giuseppe, additional, Chiusolo, Patrizia, additional, Specchia, Giorgina, additional, Guidi, Stefano, additional, Patriarca, Francesca, additional, Bacigalupo, Andrea, additional, Risitano, Antonio M., additional, Saporiti, Giorgia, additional, Pini, Massimo, additional, Pogliani, Enrico Maria, additional, Arcese, William, additional, Marotta, Giuseppe, additional, Carella, Angelo Michele, additional, Nagler, Arnon, additional, Russo, Domenico, additional, Corradini, Paolo, additional, Alessandrino, Emilio Paolo, additional, Torelli, Giovanni Fernando, additional, Scimè, Rosanna, additional, Mordini, Nicola, additional, Oldani, Elena, additional, Masciulli, Arianna, additional, Marfisi, Rosa Maria, additional, and Bosi, Alberto, additional

Published
2014
Full Text
View/download PDF

12. Alkylator-Based Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) in Lymphoma: A Registry Study Comparing Thiotepa-, Busulfan-, Melphalan- and Treosulfan-Containing Regimens On Behalf of the EBMT Lymphoma Working Party

Author

Dreger, Peter, primary, Finel, Herve, additional, Fanin, Renato, additional, Corradini, Paolo, additional, Falda, Michele, additional, Finke, Jürgen, additional, Arcese, William, additional, Galieni, Piero, additional, Castagna, Luca, additional, Russo, Domenico, additional, Brune, Mats L, additional, Scimè, Rosanna, additional, Pogliani, Enrico Maria, additional, Benedetti, Fabio, additional, Schmitz, Norbert, additional, and Boumendil, Ariane, additional

Published
2012
Full Text
View/download PDF

14. Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple Myeloma: A Study from the Italian Bone Marrow Transplantation Donor Registry

Author

Bruno, Benedetto, primary, Passera, Roberto, additional, Patriarca, Francesca, additional, Bonifazi, Francesca, additional, Montefusco, Vittorio, additional, Falda, Michele, additional, Giaccone, Luisa, additional, Montanari, Mauro, additional, Bacigalupo, Andrea, additional, Guidi, Stefano, additional, Mordini, Nicola, additional, Rambaldi, Alessandro, additional, Milone, Giuseppe, additional, Carella, Angelo Michele, additional, Bavaro, Pasqua, additional, Ciceri, Fabio, additional, Scimè, Rosanna, additional, Benedetti, Eduardo, additional, Levis, Alessandro, additional, Marenco, Paola, additional, Casini, Marco, additional, Bosi, Alberto, additional, Corradini, Paolo, additional, Bandini, Giuseppe, additional, Fanin, Renato, additional, Boccadoro, Mario, additional, and Pollichieni, Simona, additional

Published
2011
Full Text
View/download PDF

15. Sustained Responses and Resistance to Imatinib Mesylate in the First 173 Chronic Myeloid Leukemia Patients Accrued by the SCREEN Multicenter Study: First Interim Report.

Author

Vigneri, Paolo, primary, Stagno, Fabio, additional, Stella, Stefania, additional, Cupri, Alessandra, additional, Massimino, Michele, additional, Fabro, Vittorio Del, additional, Consoli, Carla, additional, Bonomo, Pietro, additional, Abbadessa, Vincenzo, additional, Brugiatelli, Maura, additional, Guglielmo, Patrizia, additional, Musolino, Caterina, additional, Scimè, Rosanna, additional, Russo, Mario, additional, Pagnucco, Guido, additional, Rizzo, Michele, additional, Musso, Maurizio, additional, Giustolisi, Rosario, additional, Messina, Angelo, additional, and Raimondo, Francesco Di, additional

Published
2009
Full Text
View/download PDF

16. Efficacy of Caspofungin as Secondary Prophylaxis in Patients Undergoing Stem Cell Transplantation with Prior Pulmonary and/or Systemic Fungal Infection.

Author

de Fabritiis, Paolo, primary, Cudillo, Laura, primary, Di Bartolomeo, Paolo, primary, Locasciulli, Anna, primary, Milone, Giuseppe, primary, Fallani, Stefania, primary, Busca, Alessandro, primary, Scimè, Rosanna, primary, Sica, Simona, primary, Spagnoli, Alessandra, primary, Santarone, Stella, primary, Majolino, Ignazio, primary, Poidomani, Massimo, primary, and Novelli, Andrea, primary

Published
2005
Full Text
View/download PDF

17. Rituximab May Allow To Improve Multi-Organ Involvement in Patients with cGVHD.

Author

Zaja, Francesco F., primary, Bacigalupo, Andrea A., primary, Bosi, Alberto A., primary, Scimè, Rosanna R., primary, Milone, Giovanna G., primary, Falda, Michele M., primary, Vener, C., primary, Laszlo, D., primary, Alessandrino, E. P., primary, Narni, F., primary, Sica, S., primary, Olivieri, A., primary, Sperotto, Alessandra A., primary, and Fanin, Renato R., primary

Published
2005
Full Text
View/download PDF

18. Effect of Age and Previous Autologous Transplant on Treatment-Related Mortality and GVHD in 140 Patients Treated with Reduce-Intensity Conditioning and Allograft for Advanced Hematological Malignancies.

Author

Corradini, Paolo, primary, Zallio, Francesco, additional, Mariotti, Jacopo, additional, Valagussa, Pinuccia, additional, Dodero, Anna, additional, Bregni, Marco, additional, Ciceri, Fabio, additional, Bacigalupo, Andrea, additional, Lucesole, Moira, additional, Patriarca, Francesca, additional, Rambaldi, Andrea, additional, Scimè, Rosanna, additional, Bandini, Giuseppe, additional, Gianni, Alessandro M., additional, Tarella, Corrado, additional, and Olivieri, Attilio, additional

Published
2004
Full Text
View/download PDF

19. Allogeneic Stem Cell Transplantation (Allo-SCT) Following a Reduced-Intensity Conditioning (RIC) Regimen in Relapsed Peripheral T-Cell Lymphomas (PTCL): Results at 4 Year of Median Follow-up.

Author

Dodero, Anna, Spina, Francesco, Narni, Franco, Patriarca, Francesca, Cortelazzo, Sergio, Benedetti, Fabio, Ciceri, Fabio, Baronciani, Donatella, Scime', Rosanna, Pogliani, Enrico, Rambaldi, Alessandro, Bonifazi, Francesca, Olivieri, Attilio, Bruno, Benedetto, Tarella, Corrado, and Corradini, Paolo

Published
2009
Full Text
View/download PDF

20. Long-Term Follow-up of Patients Affected by Relapsed Lymphomas Receiving Reduced-Intensity Conditioning (RIC) Regimen Followed by Allogeneic Stem Cell Transplantation (Allo-SCT): An Update of the Phase II Study of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO)

Author

Corradini, Paolo, Dodero, Anna, Farina, Lucia, Fanin, Roberto, Patriarca, Francesca, Miceli, Rosalba, Matteucci, Paola, Ciceri, Fabio, Scime', Rosanna, Narni, Franco, Pogliani, Enrico, Locasciulli, Anna, Dalto, Serena, Carniti, Cristiana, Bacigalupo, Andrea, Rambaldi, Alessandro, Bonifazi, Francesca, Olivieri, Attilio, Brune, Mats L, Gianni, Alessandro M., and Tarella, Corrado

Published
2008
Full Text
View/download PDF

21. Reduced Intensity Conditioning with Thiotepa and Fludarabine for Allogeneic Transplantation: Evidence for Low Toxicity and Long-Lasting Disease Control in MDS with Low/Intermediate-1 IPSS Score and in AML from MDS in Complete Remission.

Author

Alessandrino, Emilio Paolo, Malcovati, Luca, La Nasa, Giorgio, de Fabritiis, Paolo, Bernardi, Massimo, Di Bartolomeo, Paolo, Bernasconi, Paolo, Colombo, Anna A, Caldera, Daniela, Pascutto, Cristiana, Mazza, Patrizio, Narni, Franco, Scime', Rosanna, Olivieri, Attilio, Casini, Marco, and GITMO, Andrea Bacigalupo for

Published
2008
Full Text
View/download PDF

22. Repeated Courses of Bone Marrow-Derived Cell Mobilization Induced by Granulocyte-Colony Stimulating Factor (G-CSF) in Amyotrophic Lateral Sclerosis: Interim Analysis of a Prospective Multicenter Trial.

Author

Tarella, Corrado, Melazzini, Mario, Petrini, Mario, Leone, Giuseppe, Scime', Rosanna, Soligo, Davide, Gualandi, Francesca, Moglia, Cristina, Mancardi, Gianluigi, Silani, Vincenzo, La Bella, Vincenzo, Tonali, Pietro A., Siciliano, Gabriele, Mora, Gabriele, and Chio, Adriano

Published
2007
Full Text
View/download PDF

23. Unrelated Donor Hematopoietic Cell Transplantation after Non-Myeloablative Conditioning for Patients with High Risk Multiple Myeloma.

Author

Sorasio, Roberto, Giaccone, Luisa, Patriarca, Francesca, Montefusco, Vittorio, Guidi, Stefano, Busca, Alessandro, Scime', Rosanna, Console, Giuseppe, Milone, Giuseppe, Marotta, Giuseppe, Dominietto, Alida, Rotta, Marcello, Falda, Michele, Bacigalupo, Andrea, Bosi, Alberto, Corradini, Paolo, Fanin, Renato, Pollichieni, Simona, Bruno, Benedetto, and Boccadoro, Mario

Published
2006
Full Text
View/download PDF

25. Reduced-Intensity Conditioning (RIC) Followed by Allogeneic Transplantation in Relapsed Lymphomas: Evidence for Graft-Versus-Lymphoma Effect in Low and High Grade Histologies, but Not in Hodgkin Disease.

Author

Corradini, Paolo, Dodero, Anna, Bregni, Marco, Olivieri, Attilio, Farina, Lucia, Rizzo, Elena, Milani, Raffaella, Scime, Rosanna, Rambaldi, Alessandro, Bonifazi, Francesca, Patriarca, Francesca, Locasciulli, Anna, Bacigalupo, Andrea, Gianni, Alessandro Massimo, and Tarella, Corrado

Published
2004
Full Text
View/download PDF

26. Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis

Author

Maria Pia Sormani, Marco Capobianco, Matilde Inglese, Emanuele Angelucci, Rosanna Scimè, Raffaella Greco, Salvatore Cottone, Giancarlo Comi, Antonio Bertolotto, Alessio Signori, Riccardo Saccardi, Luca Massacesi, Lucia Moiola, Jessica Frau, Antonio Uccelli, Marco De Gobbi, Anna Maria Repice, Maria Pia Amato, Fabio Ciceri, Alice Mariottini, G. B. Zimatore, Francesca Gualandi, Gianluigi Mancardi, Giacomo Boffa, Chiara Innocenti, Boffa, Giacomo, Massacesi, Luca, Inglese, Matilde, Mariottini, Alice, Capobianco, Marco, Lucia, Moiola, Amato, Maria Pia, Cottone, Salvatore, Gualandi, Francesca, De Gobbi, Marco, Greco, Raffaella, Scimè, Rosanna, Frau, Jessica, Zimatore, Giovanni Bosco, Bertolotto, Antonio, Comi, Giancarlo, Uccelli, Antonio, Signori, Alessio, Angelucci, Emanuele, Innocenti, Chiara, Ciceri, Fabio, Repice, Anna Maria, Sormani, Maria Pia, Saccardi, Riccardo, and Mancardi, Gianluigi

Subjects
Oncology, 0301 basic medicine, Melphalan, medicine.medical_specialty, Expanded Disability Status Scale, business.industry, Multiple sclerosis, medicine.medical_treatment, Hazard ratio, Hematopoietic stem cell transplantation, medicine.disease, Confidence interval, Term (time), Transplantation, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Internal medicine, Medicine, Neurology (clinical), business, 030217 neurology & neurosurgery, Etoposide, medicine.drug
Abstract

ObjectiveTo determine whether autologous hematopoietic stem cell transplantation (aHSCT) is able to induce durable disease remission in people with multiple sclerosis (MS), we analyzed the long-term outcomes after transplantation in a large cohort of patients with MS.MethodsTo be included, a minimum dataset (consisting of age, MS phenotype, Expanded Disability Status Scale [EDSS] score at baseline, information on transplantation technology, and at least 1 follow-up visit after transplantation) was required.ResultsTwo hundred ten patients were included (relapsing-remitting [RR] MS 122 [58%]). Median baseline EDSS score was 6 (1–9); mean follow-up was 6.2 (±5.0) years. Among patients with RRMS, disability worsening–free survival (95% confidence interval [CI]) was 85.5% (76.9%–94.1%) at 5 years and 71.3% (57.8%–84.8%) at 10 years. In patients with progressive MS, disability worsening–free survival was 71.0% (59.4%–82.6%) and 57.2% (41.8%–72.7%) at 5 and 10 years, respectively. In patients with RRMS, EDSS significantly reduced after aHSCT (p = 0.001; mean EDSS change per year −0.09 [95% CI −0.15% to −0.04%]). In patients with RRMS, the use of the BCNU+Etoposide+Ara-C+Melphalan (BEAM) + anti-thymocyte globulin (ATG) conditioning protocol was independently associated with a reduced risk of no evidence of disease activity 3 failure (hazard ratio 0.27 [95% CI 0.14–0.50], p < 0.001). Three patients died within 100 days from aHSCT (1.4%); no deaths occurred in patients transplanted after 2007.ConclusionsaHSCT prevents disability worsening in the majority of patients and induces durable improvement in disability in patients with RRMS. The BEAM + ATG conditioning protocol is associated with a more pronounced suppression of clinical relapses and MRI inflammatory activity.Classification of EvidenceThis study provides Class IV evidence that for people with MS, aHSCT induces durable disease remission in most patients.

Published
2021
Full Text
View/download PDF

27. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial

Author

Arianna Masciulli, Maria Caterina Mico, Francesca Patriarca, Angelo Michele Carella, Emilio Paolo Alessandrino, Rosanna Scimè, Elisabetta Terruzzi, Cristina Boschini, Mauro Montanari, Paolo Corradini, Giuseppe Marotta, Arnon Nagler, Alessandro Rambaldi, Antonio M. Risitano, Stella Santarone, Benedetto Bruno, Anna De Grassi, Nicola Mordini, William Arcese, Alessandro Busca, Andrea Bacigalupo, Giovanni Fernando Torelli, Alberto Bosi, Irene Cavattoni, Domenico Russo, Elena Oldani, Roberto Raimondi, Domenico Pastore, Giuseppe Milone, Stefano Guidi, Massimo Pini, Patrizia Chiusolo, Rosa Maria Marfisi, Giorgia Saporiti, Rambaldi, Alessandro, Grassi, Anna, Masciulli, Arianna, Boschini, Cristina, Micò, Maria Caterina, Busca, Alessandro, Bruno, Benedetto, Cavattoni, Irene, Santarone, Stella, Raimondi, Roberto, Montanari, Mauro, Milone, Giuseppe, Chiusolo, Patrizia, Pastore, Domenico, Guidi, Stefano, Patriarca, Francesca, Risitano, ANTONIO MARIA, Saporiti, Giorgia, Pini, Massimo, Terruzzi, Elisabetta, Arcese, William, Marotta, Giuseppe, Carella, Angelo Michele, Nagler, Arnon, Russo, Domenico, Corradini, Paolo, Alessandrino, Emilio Paolo, Torelli, Giovanni Fernando, Scimè, Rosanna, Mordini, Nicola, Oldani, Elena, Marfisi, Rosa Maria, Bacigalupo, Andrea, and Bosi, Alberto

Subjects
Myeloid, Homologous, Adult, Male, medicine.medical_specialty, Transplantation Conditioning, Cyclophosphamide, medicine.medical_treatment, Population, Antineoplastic Agents, Hematopoietic stem cell transplantation, Acute, Antineoplastic Agent, Aged, Antineoplastic Combined Chemotherapy Protocols, Busulfan, Female, Humans, Leukemia, Myeloid, Acute, Middle Aged, Transplantation, Homologous, Vidarabine, Hematopoietic Stem Cell Transplantation, Induction Chemotherapy, Oncology, Medicine (all), hemic and lymphatic diseases, Internal medicine, medicine, education, Transplantation, Homologou, Preparative Regimen, Transplantation, education.field_of_study, Antineoplastic Combined Chemotherapy Protocol, Leukemia, business.industry, RIC, Surgery, Fludarabine, Settore MED/15 - MALATTIE DEL SANGUE, Regimen, business, Human, medicine.drug
Abstract

Summary Background The standard busulfan–cyclophosphamide myeloablative conditioning regimen is associated with substantial non-relapse mortality in patients older than 40 years with acute myeloid leukaemia who are undergoing allogeneic stem-cell transplantation. Because the combination of busulfan plus fludarabine has been proposed to reduce non-relapse mortality, we aimed to compare this treatment with busulfan plus cyclophosphamide as a preparative regimen in these patients. Methods We did an open-label, multicentre, randomised, phase 3 trial for patients with acute myeloid leukaemia at 25 hospital transplant centres in Italy and one in Israel. Eligible patients were aged 40–65 years, had an Eastern Cooperative Oncology Group performance status less than 3, and were in complete remission. Patients were randomly assigned 1:1 to receive intravenous busulfan plus cyclophosphamide or busulfan plus fludarabine. Treatment allocations were not masked to investigators or patients. Randomisation was done centrally via a dedicated web-based system using remote data entry, with patients stratified by donor type and complete remission status. Patients allocated to busulfan plus cyclophosphamide received intravenous busulfan 0·8 mg/kg four times per day during 2 h infusions for four consecutive days (16 doses from days −9 through −6; total dose 12·8 mg/kg) and cyclophosphamide at 60 mg/kg per day for two consecutive days (on days −4 and −3; total dose 120 mg/kg). Patients allocated to busulfan plus fludarabine received the same dose of intravenous busulfan (from days −6 through −3) and fludarabine at 40 mg/m 2 per day for four consecutive days (from days −6 through −3; total dose 160 mg/m 2 ). The primary endpoint was 1-year non-relapse mortality, which was assessed on an intention-to-treat basis; safety outcomes were assessed in the per-protocol population. This trial has been completed and is registered with ClinicalTrials.gov, number NCT01191957. Findings Between Jan 3, 2008, and Dec 20, 2012, we enrolled and randomly assigned 252 patients to receive busulfan plus cyclophosphamide (n=125) or busulfan plus fludarabine (n=127). Median follow-up was 27·5 months (IQR 9·8–44·3). 1-year non-relapse mortality was 17·2% (95% CI 11·6–25·4) in the busulfan plus cyclophosphamide group and 7·9% (4·3–14·3) in the busulfan plus fludarabine group (Gray's test p=0·026). The most frequently reported grade 3 or higher adverse events were gastrointestinal events (28 [23%] of 121 patients in the busulfan plus cyclophosphamide group and 26 [21%] of 124 patients in the busulfan plus fludarabine group) and infections (21 [17%] patients in the busulfan plus cyclophosphamide group and 13 [10%] patients in the busulfan plus fludarabine group had at least one such event). Interpretation In older patients with acute myeloid leukaemia, the myeloablative busulfan plus fludarabine conditioning regimen is associated with lower transplant-related mortality than busulfan plus cyclophosphamide, but retains potent antileukaemic activity. Accordingly, this regimen should be regarded as standard of care during the planning of allogeneic transplants for such patients. Funding Agenzia Italiana del Farmaco.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results